SCHEMBL4614201

SCHEMBL4614201

Cc1nn(C)c(Cl)c1S(=O)(=O)Nc1ccc(CC(=O)Nc2c(N)[nH]c(=O)n(Cc3ccccc3F)c2=O)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PCK1 P35558 7/20 0.48
SGK1 O00141 4/20 0.38
ALDH1A1 P00352 1/20 0.35
ACLY P53396 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2B Q13224 1/20 0.34
POLB P06746 3/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
PSMD14 O00487 1/20 0.33
DNMT1 P26358 1/20 0.33
APOBEC3A P31941 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CTDSP1 Q9GZU7 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
IDH1 O75874 1/20 0.33
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4616635 0.86 PCK1 (0.57) PCK1SGK1ALDH1A1ACLYPOLB
SCHEMBL4616391 0.84 PCK1 (0.56) PCK1SGK1KMT2A
SCHEMBL4615405 0.71 SGK1 (0.48) SGK1ACLY
SCHEMBL3979338 0.71 PCK1 (0.47) PCK1POLBKMT2AKDM4EMEN1
SCHEMBL4615492 0.68 PCK1 (0.54) PCK1KMT2A
SCHEMBL4614353 0.67 GLS (0.43) PCK1POLBKMT2AKDM4EMEN1
SCHEMBL4615614 0.66 PCK1 (0.56) PCK1SGK1ALDH1A1KMT2AKDM4E
SCHEMBL4615496 0.66 PCK1 (0.52) PCK1KMT2A
SCHEMBL4667200 0.65 PCK1 (0.55) PCK1SGK1KMT2A
SCHEMBL4614732 0.63 KDM4E (0.37) PCK1GRIN1GRIN2BPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1599477-B1 SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS HOFFMANN LA ROCHE (CH) 2008-01-30 EP disclosed
EP-1599477-B1 SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS HOFFMANN LA ROCHE (CH) 2008-01-30 EP disclosed
US-7148229-B2 Sulfonamide substituted xanthine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-12-12 US disclosed
US-20040192708-A1 Sulfonamide substituted xanthine derivatives DUNTEN PETER W (US) 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192708-A1 Sulfonamide substituted xanthine derivatives GYS2, SLC5A1, SLC5A2 PCK1 36/4885SGK1 461/4885ALDH1A1 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.